The short answer
Tetracycline has an established sun-sensitivity warning. St. John’s wort, or Hypericum perforatum, has shown mixed, dose-dependent sunlight effects in human studies, but the checked studies did not test it together with tetracycline. Extra risk from the exact combination remains uncertain, so have the preparation reviewed and follow the antibiotic’s sun precautions.
What this answer covers
Oral tetracycline hydrochloride and oral Hypericum perforatum extracts. LI 160 studies are ingredient-only evidence, not a direct combination trial; pure hypericin and topical products are distinct.
- Supplement or preparation
- Hypericum perforatum
- Medication ingredient
- tetracycline
What does tetracycline itself do?
Tetracycline can cause an exaggerated sunburn response. Its patient guidance recommends limiting unnecessary sunlight and using protective clothing and sunscreen, with prompt advice if a sunburn develops. That is an established medicine precaution. It should remain visible even when evidence about the additional contribution of a herbal product is uncertain.
What did the St. John’s wort trials show?
One study found little single-dose change in solar sensitivity, with a marginal selective-UVA effect at the highest dose, and modest changes after fifteen days of higher-dose extract. Another study of 72 volunteers found no meaningful phototoxicity signal at typical clinical doses of the tested extract. These results do not support treating every oral dose as equally photosensitizing.
Were people taking tetracycline in those studies?
No tetracycline co-treatment was established in these experiments. They measured the herb’s own effects under controlled light exposure. Combining two separate concerns into an additive drug interaction is a plausible question for review, but the studies do not measure the magnitude of extra risk for the pair or prove that it is absent.
What details matter for a practical plan?
Tell the pharmacist the exact extract, daily amount and other ingredients, rather than only saying St. John’s wort. The research used LI 160, and pure hypericin or a different preparation cannot automatically be assigned the same result. Follow tetracycline’s sun advice and have all medicines and herbal products considered together before changing the treatment plan.
Evidence and practical considerations
Side effects & toxicity
Tetracycline has an established sun-sensitivity warning. St. John’s wort, or Hypericum perforatum, has shown mixed, dose-dependent sunlight effects in human studies, but the checked studies did not test it together with tetracycline. Extra risk from the exact combination remains uncertain, so have the preparation reviewed and follow the antibiotic’s sun precautions.
- Exact scope
- oral Hypericum perforatum extracts, with LI 160 and hypericin exposure distinguished with oral tetracycline hydrochloride capsules, 250 mg or 500 mg salt strength
- Medication form and route
- oral
- Timing or duration
- Herb studies used single doses, seven-day or fifteen-day regimens; no exact pair treatment duration studied.
What remains uncertain
- No direct tetracycline/Hypericum trial found. Higher-dose ingredient evidence and a largely negative typical-dose study must both be retained; additive clinical risk is not quantified.
Factors that may matter: extract identity and hypericin content; daily dose and duration; sunlight and ultraviolet exposure; skin type; other photosensitizing medicines.
Read the supporting source summaries
Source 1: regulatory product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral tetracycline hydrochloride capsules.
Names aluminum/calcium/magnesium antacids and iron, zinc or sodium bicarbonate preparations as absorption interferents. Food and some dairy products interfere. Warns of exaggerated sunburn reactions. Does not name potassium citrate or the two botanical pairs.
How this applies: The specific monohydrochloride chemical description provides a bounded oral salt formulation for parent tetracycline RxCUI 10395. Doxycycline, minocycline and chlortetracycline results are not treated as tetracycline results. Article-specific counterparty: oral Hypericum perforatum extracts, with LI 160 and hypericin exposure distinguished.
Uses some class wording; no universal numeric mineral interval or all-salt effect size is supplied. Its sodium-bicarbonate statement differs from one small retrieved clinical trial.
Source 2: institutional patient medication guidance
medlineplus.gov · Source check Sep 10, 2026
Population: People prescribed oral tetracycline.
Places calcium/antacids/magnesium laxatives 6 hours before or 2 hours after tetracycline; iron 4 hours before or 2 hours after. Includes inconsistent zinc timing sentences: first with the six-hour group, then two hours in either direction. Also gives empty-stomach and sun-protection advice.
How this applies: Exact tetracycline medication page. Calcium-supplement wording is broader than antacid-only labeling; the scope bridge must be explicit for calcium citrate. Article-specific counterparty: oral Hypericum perforatum extracts, with LI 160 and hypericin exposure distinguished.
Secondary patient guidance rather than a clinical experiment. Zinc timing is internally inconsistent and cannot be presented as a single unambiguous interval.
Source 3: original human clinical study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 13 volunteers in randomized placebo-controlled single-dose crossover; 50 in repeated-dose study.
Single-dose solar sensitivity did not change; highest dose marginally increased selective UVA sensitivity. Repeated high doses modestly increased sensitivity. Authors noted doses above typical commercial use.
How this applies: Direct for oral Hypericum perforatum LI 160 only; separate ingredient effect, not demonstrated additive drug-pair risk. Article-specific counterparty: oral Hypericum perforatum extracts, with LI 160 and hypericin exposure distinguished.
No tetracycline co-treatment. Preparation-specific results, marginal single-dose statistics and high exposure limit transfer to usual doses. Full clinical article was not inspected; original author abstract was read.
Source 4: original human clinical study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 72 volunteers with skin types II and III in six groups of 12.
No significant erythema or pigmentation effect apart from marginal UVB pigmentation in single-dose testing. Authors did not find phototoxicity at typical clinical doses up to 1800 mg daily.
How this applies: Contrary human ingredient-only evidence is preserved; it does not prove the pair safe. Article-specific counterparty: oral Hypericum perforatum extracts, with LI 160 and hypericin exposure distinguished.
Short controlled exposure and specific extract; no tetracycline and no clearance for all extracts or unusually intense sunlight. Full clinical article was not inspected; original author abstract was read.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Exact-drug product guidance and original research checked; complete private article prepared with evidence limitations and current-claim adjudication. | |
| Research summary published |
Article revision: 119df919c56bf34d
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.